证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2022003 | --- | --- | |-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2022001 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 编号：2022005 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------| | 投资者关系活动 类别 | 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他（网络会议） | | 参与单位名称及 人员姓名 | 华西证券（戚舒扬） | | 时间 | 2022 年 6 月 2 日下午 16:00—17:00 | | 地点 | 中金辐照会议室 | | 上市公司接待人 员姓名 | 副总经理：于梅 董事会秘书：杨先刚 证券事务代表：曹婷 | | | 1 、医疗保健和食品灭菌行业成长性驱动力在什么地方？ | | | 答：公司主要利用钴 -60 以及电子加速器为客户提供医疗 | | | 保健产品、食品、药品、日用品、包装材料等产品的辐照灭菌 服务， ...

证券代码：300962 证券简称：中金辐照 中金辐照股份有限公司 投资者关系活动记录表 | --- | --- | |-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 投资者关系活动 类别 | 编号： 2022007 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他（ 2022 深 圳辖区上市公司投资者网上集体接待日活动） | | 参与单位名称及 人员姓名 | 通过"全景路演"网站远程参与集体接待日活动的广大投资者 | | 时间 | 2022 年 11 月 9 日下午 16:30—17:30 | | 地点 | "全景路演"网站（ http://rs.p5w.net ） | | 上市公司接待人 员姓名 | 总会计师张 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥88,841,696.65, representing a 7.69% increase year-over-year[5]. - Net profit attributable to shareholders for Q3 2022 was ¥34,266,430.17, up 19.94% compared to the same period last year[5]. - The basic earnings per share for Q3 2022 was ¥0.1298, reflecting a 19.96% increase year-over-year[5]. - Total operating revenue for Q3 2022 was ¥252,309,741.11, an increase of 9.8% from ¥229,842,284.49 in the same period last year[18]. - Operating profit for Q3 2022 reached ¥114,970,172.21, up 16.8% from ¥98,499,484.91 in Q3 2021[18]. - Net profit attributable to shareholders of the parent company was ¥93,909,975.51, representing a 15.5% increase compared to ¥81,372,705.04 in the previous year[19]. - Total profit for Q3 2022 was ¥114,999,930.39, an increase of 16.9% from ¥98,294,966.24 in the same period last year[18]. Assets and Liabilities - Total assets at the end of Q3 2022 reached ¥1,081,407,082.95, an increase of 8.01% from the end of the previous year[5]. - Accounts receivable increased by 97.91% compared to the end of the previous year, attributed to enhanced market development efforts[8]. - Prepaid accounts increased by 865.38% compared to the end of the previous year, mainly due to increased advance payments to suppliers[8]. - The total current liabilities increased to CNY 40,050,650.06 from CNY 29,207,276.75, representing an increase of approximately 37.0%[16]. - The company's total equity reached CNY 946,011,618.16, up from CNY 877,004,256.30, marking an increase of about 7.9%[16]. - The company's retained earnings increased to CNY 352,123,281.49 from CNY 292,063,578.23, reflecting a growth of approximately 20.6%[16]. - The company reported a significant decrease in accounts payable, which fell to CNY 4,783,461.77 from CNY 10,932,823.36, a reduction of about 56.2%[16]. - The company’s non-current liabilities totaled CNY 95,344,814.73, slightly up from CNY 95,023,989.52, indicating a marginal increase[16]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥152,445,638.16, down 7.81% compared to the previous year[5]. - Cash flow from operating activities was ¥152,445,638.16, down 7.7% from ¥165,362,246.87 in Q3 2021[21]. - The company reported a net cash outflow from investing activities of ¥60,426,828.52, compared to a net outflow of ¥38,914,024.11 in the previous year[22]. - The company experienced a decrease in cash flow from financing activities, with a net outflow of ¥26,141,278.86 compared to a net inflow of ¥132,421,628.25 in Q3 2021[22]. - Cash and cash equivalents at the end of the period totaled ¥381,342,399.31, an increase from ¥297,006,540.87 at the end of Q3 2021[22]. - The company's cash and cash equivalents increased to CNY 381,342,399.31 from CNY 315,464,868.53, reflecting a growth of approximately 20.9%[15]. Expenses and Tax - The company reported a 36.26% increase in income tax expenses year-to-date, driven by increased revenue and profit[9]. - Non-operating income for the year-to-date period decreased by 81.70% compared to the previous year, primarily due to reduced asset disposal gains from subsidiaries[9]. - Research and development expenses increased to ¥15,577,565.53, up 25.3% from ¥12,471,888.52 in the same quarter last year[18]. Government Support and Investments - The company received government subsidies amounting to ¥1,058,099.72 in Q3 2022, contributing to its non-recurring gains[6]. - The company has ongoing investments in construction projects, with construction in progress valued at CNY 63,757,185.53, up from CNY 29,756,359.35[15]. Market and Product Development - The company has not disclosed any new product developments or market expansion strategies in the current report[14].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥163,468,044.46, representing a 10.94% increase compared to ¥147,347,563.20 in the same period last year[20]. - The net profit attributable to shareholders was ¥59,643,545.34, up 12.95% from ¥52,804,172.82 year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥58,894,605.03, reflecting a significant increase of 22.94% compared to ¥47,905,659.83 in the previous year[20]. - The net cash flow from operating activities decreased by 17.53% to ¥98,103,005.87 from ¥118,958,590.21 in the same period last year[20]. - Total assets at the end of the reporting period were ¥1,039,787,532.72, a 3.85% increase from ¥1,001,235,522.57 at the end of the previous year[20]. - The net assets attributable to shareholders increased by 3.93% to ¥878,796,762.28 from ¥845,553,406.64 at the end of the previous year[20]. - The basic earnings per share were ¥0.2259, a slight decrease of 1.18% from ¥0.2286 in the same period last year[20]. - The weighted average return on equity was 6.85%, down from 7.71% in the previous year[20]. - The company reported a steady increase in revenue and profit due to the rising demand for sterilization services in the healthcare sector, driven by the ongoing pandemic[51]. Business Operations - The main business of the company is irradiation technology services, primarily providing sterilization services for healthcare products, food, pharmaceuticals, and packaging materials, which is the main source of revenue and profit[28]. - The company utilizes cobalt-60 and electron beam technology for sterilization, ensuring effective sterilization without contamination or residue, maintaining a sterile state for healthcare products[30]. - The irradiation sterilization services cover various sectors, including healthcare products, food, pharmaceuticals, and packaging materials, with a focus on maintaining product quality and extending shelf life[31][32][33]. - The company has established regional centers in seven major cities, implementing a unified planning and regional operation model to enhance service delivery and market expansion[38]. - The revenue from irradiation technology services has shown an upward trend due to increasing demand driven by economic growth and continuous market development by subsidiaries[40]. - The company emphasizes personalized services tailored to customer specifications, which helps build strong customer loyalty and relationships[40]. - The company’s fixed costs, including depreciation of irradiation equipment, are significant, and profitability increases rapidly as revenue scales up after the initial market development phase[40]. - The procurement model is based on demand, with a strict budget management system in place for purchasing, particularly for cobalt sources used in irradiation services[41]. - The company must obtain various regulatory approvals for the procurement and transportation of radioactive cobalt sources, ensuring compliance with safety and environmental regulations[41]. - The company operates 10 gamma irradiation devices and 1 electron accelerator across 7 regional centers in China, with ongoing projects in Zhejiang and Chengdu to expand capacity[42]. - The company has established a quality management system compliant with international standards, receiving certifications from BSI, TUV, and others, ensuring service quality and compliance with national and international standards[44]. - The company has a stable customer base, primarily large companies with stringent supplier certification processes, leading to consistent and increasing demand for sterilization services[46]. Research and Development - Research and development investment increased by 31.45%, reaching approximately ¥9.90 million, up from ¥7.53 million in the previous year[67]. - The company established 30 new R&D projects in the first half of 2022, including the study of dose distribution in electron accelerator irradiation processing[53]. - The company holds a stable core technical team, with no significant changes reported during the reporting period[54]. - The company has developed its own irradiation information management system to enhance operational efficiency and service traceability[45]. - The company is actively promoting new irradiation technologies and applications to enhance market competitiveness and expand its market share[51]. Financial Management - The company plans to distribute a cash dividend of ¥1.50 per 10 shares, totaling approximately ¥39,600,284.55 based on 264,001,897 shares[4]. - The company received government subsidies amounting to ¥871,618.82 during the reporting period, contributing to its financial performance[24]. - The company has implemented a centralized management model for cobalt source procurement, which helps reduce costs and improve resource allocation efficiency[63]. - The company reported a significant increase in financial expenses, with a decrease of 431.62% due to no borrowings and increased interest income from deposits[67]. - The company has a comprehensive quality management system that complies with multiple international standards, ensuring effective quality control and management[56]. Market Strategy - The company plans to enhance its market development efforts, particularly in new fields of irradiation technology applications and disinfection supply services, to further improve operational performance[91]. - The company aims to expand its customer base for irradiation services and increase new profit growth points amid ongoing pandemic challenges[90]. - The company has expanded its irradiation service network across key economic regions, including the Yangtze River Economic Belt and the Guangdong-Hong Kong-Macao Greater Bay Area[59]. - The company is committed to enhancing its core competitiveness and market expansion strategies in response to industry trends[91]. Shareholder and Compliance - The company has committed to protecting shareholder rights and ensuring equal treatment for all shareholders[104]. - The company will ensure compliance with any regulatory restrictions on share circulation[110]. - The company has fulfilled its commitments regarding share transfers as of April 2022[110]. - The company will disclose specific reasons for any failure to fulfill commitments in a timely manner[127]. - The company commits to compensating investors for losses caused by false statements or omissions in the public offering documents[127]. - The company will accept supervision from regulatory authorities to ensure compliance with public commitments[127]. Social Responsibility - The company actively engages in social responsibility initiatives, including blood donation activities and purchasing unsold agricultural products to support impoverished areas[106]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. - The company’s subsidiaries comply with national environmental protection standards and regulations[103].

Financial Performance - The company's operating revenue for 2021 was CNY 309,072,018.55, representing a 20.75% increase compared to CNY 255,963,220.94 in 2020[17]. - The net profit attributable to shareholders for 2021 was CNY 87,119,688.54, a 41.57% increase from CNY 61,538,234.33 in 2020[17]. - The net profit after deducting non-recurring gains and losses was CNY 80,371,540.97, up 34.76% from CNY 59,640,775.03 in 2020[17]. - The net cash flow from operating activities was CNY 175,550,139.58, an increase of 24.93% compared to CNY 140,517,444.56 in 2020[17]. - The total assets at the end of 2021 reached CNY 1,001,235,522.57, a 37.14% increase from CNY 730,072,786.50 at the end of 2020[17]. - The net assets attributable to shareholders at the end of 2021 were CNY 845,553,406.64, reflecting a 40.65% increase from CNY 601,175,030.08 at the end of 2020[17]. - The basic earnings per share for 2021 were CNY 0.3520, a 13.26% increase from CNY 0.3108 in 2020[17]. - The weighted average return on equity for 2021 was 11.27%, up from 9.78% in 2020[17]. Revenue Sources and Growth - The company's total revenue for the four quarters was approximately 309.07 million, with the highest revenue in Q3 at 82.49 million, representing a 20% increase from Q1[19]. - The revenue from irradiation technology services accounted for 92.22% of total revenue, amounting to ¥285,019,312.30, with a year-on-year growth of 22.25%[73]. - The main source of revenue is from irradiation technology services, with an upward trend in profitability due to increasing demand and market expansion[40]. - The company is focused on expanding its irradiation sterilization services for medical products, food, and packaging materials, which are its main revenue sources[29]. Research and Development - Research and development expenses amounted to CNY 21,089,583.24, an increase of 18.23% year-on-year, indicating a rise in R&D investment[68]. - The company launched 34 new technology research projects in 2021, including automatic systems for gamma irradiation facilities, and obtained 2 invention patents and 26 utility model patents[54]. - The company added 26 new technology research and development patents and 7 software copyrights in 2021, bringing the total to 179 patents and 65 copyrights[71]. - The number of R&D personnel increased by 19.13% from 115 in 2020 to 137 in 2021, with R&D personnel now accounting for 24.29% of the total workforce[88]. Operational Efficiency - The operational efficiency improved with a 9.3 million CNY increase in labor productivity per person compared to the previous year[70]. - The company has implemented an information management system to improve operational efficiency and service traceability[45]. - The company has established a quality management system compliant with international standards, ensuring service quality and customer satisfaction[44]. - The company has maintained stable operational performance despite local pandemic outbreaks, providing uninterrupted irradiation sterilization services for medical products[51]. Market Expansion and Strategy - The company is actively seeking new growth opportunities through both organic growth and external expansion, aiming to increase its market presence and investment layout[115]. - The company has expanded its irradiation service network across key economic regions, enhancing its market presence and reducing single-market risks[60]. - The company is developing a project in Zhejiang for sterilizing 300,000 cubic meters of medical devices annually, indicating market expansion efforts[43]. - The company achieved a significant revenue increase in the Central China region, with a growth rate of 58.70%[74]. Governance and Compliance - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with legal regulations[128]. - The company maintains independent operations in terms of assets, personnel, finance, organization, and business, with no asset occupation by the controlling shareholder[132][133]. - The company has not faced any penalties from securities regulatory authorities in the past three years, indicating a clean compliance record[160]. - The company has a comprehensive strategy for talent management, focusing on performance evaluation and compensation linked to company performance[161]. Shareholder Engagement - The company held two shareholder meetings during the reporting period, both conducted with a combination of on-site and online voting, ensuring all resolutions were passed legally and effectively[124]. - A total of 13 questions were raised by investors during the online earnings briefing, focusing on operational performance, pandemic impacts, quality advantages, and business development[120]. - The annual shareholders meeting had a participation rate of 69.58% on May 18, 2021[138]. - The first extraordinary shareholders meeting had a participation rate of 60.00% on December 29, 2021[138]. Corporate Social Responsibility - The company actively fulfills its corporate social responsibility by promoting safety, health, and environmental protection[188]. - The company provided sterilization services for epidemic prevention products, generating approximately 900 million yuan in revenue for the year 2021[192]. - The company received recognition from the National Atomic Energy Agency and industry associations for its outstanding contributions during the pandemic[192]. - The company actively participated in social responsibility initiatives, including poverty alleviation and support for children in need[193]. Future Outlook - The company aims to achieve an annual revenue target of 322.02 million and a net profit target of 90.10 million for 2022, indicating a growth strategy focused on expanding market share[115]. - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues to reach approximately 1.65 billion RMB[150]. - The company is positioned to benefit from favorable industry policies and a growing market demand for non-power nuclear technology applications, which are recognized as strategic emerging industries[112][114].

Financial Performance - The company's operating revenue for Q1 2022 was ¥78,834,006.63, representing a 15.00% increase compared to ¥68,551,289.98 in the same period last year[4] - The net profit attributable to shareholders for Q1 2022 was ¥28,482,576.99, a 24.43% increase from ¥22,890,054.71 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥28,140,472.98, up 27.40% from ¥22,087,724.13 in the previous year[4] - The net cash flow from operating activities for Q1 2022 was ¥38,146,128.83, reflecting a 27.18% increase compared to ¥29,993,137.21 in the same period last year[4] - Total operating revenue for Q1 2022 was CNY 78,834,006.63, an increase from CNY 68,551,289.98 in the previous period[16] - Net profit for Q1 2022 reached CNY 29,469,515.58, up from CNY 23,295,330.69 in the same period last year, representing a growth of approximately 26.5%[17] - The total comprehensive income for Q1 2022 was ¥29,469,515.58, up from ¥23,295,330.69 in Q1 2021, reflecting an increase of 26.5%[18] Cash Flow and Investments - The net cash flow from operating activities for Q1 2022 was ¥38,146,128.83, an increase of 27.1% compared to ¥29,993,137.21 in Q1 2021[20] - Total cash inflow from operating activities was ¥73,072,873.94, compared to ¥65,825,411.63 in the previous year, indicating a growth of 10.2%[20] - The total cash outflow from operating activities was ¥34,926,745.11, slightly down from ¥35,832,274.42 in Q1 2021, showing a decrease of 2.5%[20] - The cash and cash equivalents at the end of Q1 2022 amounted to ¥336,538,005.28, an increase from ¥260,117,956.74 at the end of Q1 2021, representing a growth of 29.3%[22] - The company reported a net cash outflow from investing activities of ¥16,782,677.28, compared to a net outflow of ¥16,556,230.77 in the same period last year[22] - The net cash flow from financing activities was negative at ¥290,314.80, a significant decrease from a positive cash flow of ¥208,544,360.38 in Q1 2021[22] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,033,994,702.85, a 3.27% increase from ¥1,001,235,522.57 at the end of the previous year[4] - Total liabilities stood at CNY 127,520,930.97, slightly up from CNY 124,231,266.27 at the start of the year[14] - The company's total equity increased to CNY 906,473,771.88 from CNY 877,004,256.30 at the beginning of the year, reflecting a growth of approximately 3.4%[14] - Cash and cash equivalents increased to CNY 336,538,005.28 from CNY 315,464,868.53 at the beginning of the year, reflecting a growth of approximately 6.8%[12] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,451[8] - The basic and diluted earnings per share for Q1 2022 were both ¥0.1079, up from ¥0.0882 in Q1 2021, reflecting a growth of 22.4%[18] Research and Development - Research and development expenses increased by 37.91% year-on-year, indicating a focus on expanding the application of irradiation technology[7] - Research and development expenses for Q1 2022 were CNY 4,477,839.20, compared to CNY 3,246,845.81 in the previous year, marking an increase of about 38.0%[17] Accounts Receivable and Prepayments - Accounts receivable grew by 90.33% compared to the end of the previous year, attributed to increased market development efforts and significant revenue growth[7] - Prepayments increased by 1012.99% compared to the end of the previous year, primarily due to increased advance payments to suppliers[7] - Accounts receivable rose to CNY 30,407,601.17, up from CNY 15,975,952.18, indicating a significant increase of about 90.5%[12] Inventory - Inventory decreased to CNY 341,900.43 from CNY 701,855.18, showing a reduction of approximately 51.3%[12] Tax Refunds - The company received tax refunds amounting to ¥1,000,304.11 during Q1 2022, compared to ¥1,233.98 in the previous year, indicating a substantial increase[20]

Financial Performance - Revenue for Q3 2021 reached ¥82,494,721.29, an increase of 18.58% year-over-year, and total revenue for the year-to-date was ¥229,842,284.49, up 26.29% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2021 was ¥28,568,532.22, representing a growth of 30.36% year-over-year, while year-to-date net profit reached ¥81,372,705.04, up 75.09% compared to the same period last year[2]. - Operating revenue for the current period was CNY 229,842,284.49, compared to CNY 181,993,794.80 in the previous period, reflecting an increase of approximately 26.3%[15]. - The net profit for Q3 2021 was 85,211,162.32, a significant increase from 46,518,506.98 in Q3 2020, representing an increase of approximately 83.1%[16]. - Basic and diluted earnings per share for Q3 2021 were both 0.3362, compared to 0.2347 in Q3 2020, reflecting a growth of about 43.4%[17]. - Operating profit for Q3 2021 reached 98,499,484.91, up from 55,840,776.44 in the same period last year, indicating an increase of approximately 76.3%[16]. - Total comprehensive income for Q3 2021 was 85,211,162.32, compared to 46,518,506.98 in Q3 2020, showing an increase of approximately 83.1%[16]. - The total revenue from sales of goods and services received in Q3 2021 was 233,760,003.23, compared to 196,116,048.16 in Q3 2020, reflecting an increase of approximately 19.2%[18]. Assets and Liabilities - The company's total assets at the end of the reporting period were ¥999,228,971.38, a 36.87% increase from the end of the previous year[2]. - As of September 30, 2021, total assets amounted to CNY 999,228,971.38, an increase from CNY 730,072,786.50 at the end of 2020, representing a growth of approximately 36.8%[12]. - Total current assets reached CNY 357,135,462.97, significantly up from CNY 77,414,229.84, indicating a growth of about 360.5%[13]. - The total liabilities amounted to CNY 127,820,754.81, compared to CNY 100,591,420.27 in the previous period, indicating an increase of approximately 26.9%[14]. - The company's equity attributable to shareholders reached CNY 839,806,423.14, up from CNY 601,175,030.08, representing a growth of about 39.6%[14]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥165,362,246.87, reflecting a 62.31% increase compared to the previous year[2]. - Cash flow from operating activities for Q3 2021 was 165,362,246.87, compared to 101,883,206.69 in Q3 2020, marking an increase of about 62.3%[18]. - The company reported cash and cash equivalents of CNY 297,006,540.87 as of September 30, 2021, a significant increase from CNY 38,136,107.20 at the end of 2020[12]. - Cash and cash equivalents at the end of Q3 2021 amounted to 297,006,540.87, up from 75,690,961.49 at the end of Q3 2020, representing an increase of about 292.5%[19]. - The company reported a net cash outflow from investing activities of -38,914,024.11 for Q3 2021, an improvement from -56,755,699.76 in Q3 2020[19]. - Cash flow from financing activities for Q3 2021 was 132,421,628.25, compared to -31,433,490.81 in Q3 2020, indicating a turnaround in financing activities[19]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,598, with the largest shareholder, China National Gold Group Corporation, holding 54.20% of the shares[8]. Expenses and Investments - The company experienced a 34.27% decrease in sales expenses year-to-date, mainly due to the reclassification of transportation costs to operating costs under new revenue recognition standards[6]. - Research and development expenses for the current period were CNY 12,471,888.52, compared to CNY 10,990,355.55 in the previous period, reflecting an increase of approximately 13.5%[15]. - The company plans to invest CNY 45 million in the expansion of the electronic accelerator project in Chengdu, covering an area of approximately 9 acres[10]. - The company aims to enhance regional market competitiveness through the new electronic accelerator project, which will complement existing facilities[10]. Other Income and Receivables - The company reported a 124.55% increase in other income year-to-date, primarily due to increased government subsidies and compensation received[6]. - Accounts receivable increased by 101.40% compared to the end of the previous year, attributed to increased market development efforts and new customer acquisition[6]. Earnings Per Share - The company's basic earnings per share for Q3 2021 was ¥0.1082, a decrease of 2.26% year-over-year, while diluted earnings per share remained the same[2].

Financial Performance - The company's operating revenue for the first half of 2021 was RMB 147,347,563.20, representing a 31.06% increase compared to RMB 112,426,661.13 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached RMB 52,804,172.82, a significant increase of 115.00% from RMB 24,560,549.97 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was RMB 47,905,659.83, up 103.72% from RMB 23,515,359.25 year-on-year[20]. - The net cash flow from operating activities was RMB 118,958,590.21, reflecting a 105.37% increase compared to RMB 57,924,775.70 in the same period last year[20]. - Basic earnings per share increased by 84.35% to RMB 0.2286 from RMB 0.1240 in the previous year[20]. - The gross profit margin for irradiation technology services was 64.33%, up by 7.07% compared to the previous year, indicating improved efficiency[69]. - The company reported a significant increase in cash and cash equivalents, which rose by 692.37% to RMB 235,006,637.67, primarily due to funds raised from its public offering[67]. - The company's total equity rose to CNY 841,977,917.25 from CNY 629,481,366.23, reflecting an increase of approximately 33.7%[156]. - The company reported a comprehensive income total of CNY 21,896,607.26, compared to CNY 9,216,576.55 in the previous year[169]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 970,279,685.79, a 32.90% increase from RMB 730,072,786.50 at the end of the previous year[20]. - The total amount of funds raised is RMB 19,949.90 million, with RMB 3,616.39 million utilized during the reporting period and a cumulative investment of RMB 7,872.77 million as of the end of the reporting period[78]. - Total current liabilities decreased to CNY 33,072,136.74 from CNY 53,656,863.05, a reduction of about 38.5%[155]. - The company's accounts receivable increased to CNY 27,344,508.09 from CNY 15,618,327.32, which is an increase of approximately 74.9%[153]. - The company's long-term payables increased significantly to CNY 38,399,478.17 from CNY 1,526,279.61, representing a growth of approximately 2515.5%[155]. Market and Operations - The company primarily provides irradiation sterilization services for medical products, food, pharmaceuticals, and packaging materials, which are its main sources of revenue and profit[30]. - The company operates in seven regional centers across major cities, providing stable and reliable irradiation services[41]. - The company has seen significant growth in the domestic irradiation technology service industry, with increasing market demand and improved technology levels[29]. - The company is a leading enterprise in the irradiation technology service industry in China, with a national layout of 10 gamma irradiation facilities and 1 electron accelerator facility[53]. - The company has established long-term stable partnerships with over 30 Fortune 500 companies, including Johnson & Johnson and Asahi Kasei, contributing to a strong customer base[62]. Research and Development - The company has invested in 34 new technology research projects in the first half of 2021, including the development of an automatic switching system for gamma irradiation facilities[57]. - Research and development expenses increased slightly by 2.02% to ¥7,529,989.48, reflecting ongoing investment in innovation[67]. - The company has allocated CNY 300,000 million for new technology research and development initiatives[185]. Risk Management - The company emphasizes the importance of risk awareness and has outlined its risk management strategies in the report[5]. - The company is facing risks related to potential COVID-19 outbreaks, market demand fluctuations, and safety and environmental concerns, and is taking measures to mitigate these risks[89]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[95]. - The largest shareholder, China Gold Group, holds 54.20% of the shares, totaling 143,099,938 shares[138]. - The total number of ordinary shareholders at the end of the reporting period was 34,710[137]. - The net amount raised from the IPO was RMB 199.50 million, which will be used for future business expansion and development[135]. Compliance and Governance - The semi-annual financial report has not been audited[109]. - The company has ensured effective communication with investors through multiple platforms, respecting the rights of minority shareholders[99]. - There were no significant environmental penalties or violations reported during the period[98].